Department of Urology, Queen Elizabeth Hospital, Woolwich, London, UK.
Department of Urology, Queen Elizabeth Hospital, Woolwich, London, UK.
Eur Urol Focus. 2020 Jan 15;6(1):95-101. doi: 10.1016/j.euf.2018.06.016. Epub 2018 Jul 6.
Sepsis is a severe complication following transrectal ultrasound-guided prostate biopsy (TRUSPBx). Ciprofloxacin is commonly used for prophylaxis; however, there is an increasing incidence of resistant enteric organisms worldwide.
To investigate the effect of a targeted prophylactic antimicrobial regimen based on rectal swab cultures in reducing the rate of sepsis.
DESIGN, SETTING, AND PARTICIPANTS: A total of 1012 patients were included. Group A (609 patients) received an empirical prophylactic antimicrobial regimen of gentamicin, metronidazole, and ciprofloxacin. Targeted antimicrobial prophylaxis was introduced due to significant ciprofloxacin and gentamicin resistance in patients admitted with sepsis following TRUSPBx. The remaining 403 patients (Group B) had rectal swab cultures performed prior to biopsy. Patients with organisms resistant to ciprofloxacin or gentamicin received a targeted prophylaxis regimen of fosfomycin, amikacin, and metronidazole.
We retrospectively collected and analysed data on sepsis and bacteraemia for all patients as well as data on rectal swab culture, recent foreign travel, and recent antibiotic use for patients in Group B.
In group A, 12 (2.0%) patients developed sepsis following TRUSPBx, while in group B, 9 (2.2%) patients developed sepsis despite targeted prophylaxis (p=0.82). Patients with ciprofloxacin-resistant rectal flora had a significantly higher rate of sepsis (9.1% vs 1.1%; p=0.003). There was a reduction in patients admitted with bacteraemia and severe sepsis between group A (1.2%) and group B (0.3%) which did not reach statistical significance (p=0.16). In group B, 55 of 403 (13.6%) patients had ciprofloxacin-resistant rectal flora, while 66 (16.4%) had organisms resistant to both ciprofloxacin and gentamicin. A recent foreign travel history was associated with an increased incidence of ciprofloxacin-resistant rectal flora (23.6% vs 10.8%; p=0.007). The main limitations of our study include its retrospective nature and potential under-reporting of less severe infectious complications.
Rectal swab cultures identify patients with ciprofloxacin-resistant rectal flora who have an eight-fold risk of sepsis. Targeted antimicrobial prophylaxis may not be beneficial in reducing the sepsis rate when compared with augmented empirical prophylaxis. In an era of increasing antimicrobial resistance, transperineal prostate biopsies should be considered to reduce the risk of infective complications.
Performing rectal swab culture prior to transrectal prostate biopsy can help identify patients at risk of developing sepsis despite targeted prophylactic antibiotics.
败血症是经直肠超声引导前列腺活检(TRUSPBx)后的一种严重并发症。环丙沙星通常用于预防,但世界各地肠内耐药菌的发生率正在上升。
研究基于直肠拭子培养的靶向预防抗菌方案对降低败血症发生率的影响。
设计、地点和参与者:共纳入 1012 例患者。A 组(609 例)接受庆大霉素、甲硝唑和环丙沙星经验性预防抗菌治疗。由于 TRUSPBx 后败血症患者中存在显著的环丙沙星和庆大霉素耐药菌,引入了靶向抗菌预防。其余 403 例(B 组)在活检前进行直肠拭子培养。对环丙沙星或庆大霉素耐药的患者给予磷霉素、阿米卡星和甲硝唑的靶向预防方案。
我们回顾性收集和分析了所有患者的败血症和菌血症数据,以及 B 组患者的直肠拭子培养、近期出国旅行和近期抗生素使用数据。
A 组中有 12 例(2.0%)患者在 TRUSPBx 后发生败血症,而 B 组中有 9 例(2.2%)患者尽管进行了靶向预防仍发生败血症(p=0.82)。对环丙沙星耐药的直肠菌群患者败血症发生率明显更高(9.1%比 1.1%;p=0.003)。A 组(1.2%)和 B 组(0.3%)因菌血症和严重败血症入院的患者有所减少,但差异无统计学意义(p=0.16)。B 组 403 例患者中有 55 例(13.6%)直肠菌群对环丙沙星耐药,66 例(16.4%)对环丙沙星和庆大霉素均耐药。近期出国旅行史与对环丙沙星耐药的直肠菌群发生率增加相关(23.6%比 10.8%;p=0.007)。本研究的主要局限性包括其回顾性和潜在的对较轻的感染性并发症报告不足。
直肠拭子培养可识别出对环丙沙星耐药的直肠菌群患者,其败血症风险增加 8 倍。与增强的经验性预防相比,靶向抗菌预防可能并不能降低败血症的发生率。在抗菌药物耐药性日益增加的时代,经会阴前列腺活检应考虑降低感染性并发症的风险。
经直肠前列腺活检前进行直肠拭子培养有助于识别尽管使用靶向预防性抗生素仍有发生败血症风险的患者。